1. Home
  2. ELME vs MOLN Comparison

ELME vs MOLN Comparison

Compare ELME & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elme Communities

ELME

Elme Communities

HOLD

Current Price

$2.04

Market Cap

198.2M

Sector

Real Estate

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.04

Market Cap

158.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ELME
MOLN
Founded
1960
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
198.2M
158.9M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
ELME
MOLN
Price
$2.04
$4.04
Analyst Decision
Hold
Buy
Analyst Count
3
2
Target Price
$12.67
$8.38
AVG Volume (30 Days)
1.4M
3.7K
Earning Date
04-30-2026
05-14-2026
Dividend Yield
741.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$206,360,000.00
N/A
Revenue This Year
$5.03
N/A
Revenue Next Year
$4.31
$318.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.98
$3.36
52 Week High
$17.68
$5.36

Technical Indicators

Market Signals
Indicator
ELME
MOLN
Relative Strength Index (RSI) 23.19 39.49
Support Level $1.98 $4.04
Resistance Level $2.26 $4.51
Average True Range (ATR) 0.05 0.17
MACD 0.08 -0.06
Stochastic Oscillator 29.63 30.16

Price Performance

Historical Comparison
ELME
MOLN

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: